Kairos Pharma signs research agreement with Bayer to test ENV-105 with XOFIGO in prostate cancer
The deal supplies radium for a study combining carotuximab with Bayer's radiopharmaceutical in bone-involved metastatic castration-resistant prostate cancer.
SEC filing (2)